ASCIA News
-
ASCIA COVID-19 Update
24 March 2020: ASCIA COVID-19 website updates The ASCIA COVID-19 webpage www.allergy.org.au/members/covid-19 is reviewed on a daily basis and updated as required. The latest updates are as follows: The ASCIA 2020 Conference has been postponed to September 2021. This will be... -
ASCIA Annual Conference postponed to September 2021
23 March 2020: ASCIA has closely monitored the COVID-19 outbreak in relation to the ASCIA 2020 Conference, which was scheduled for the first week of September 2020 in Melbourne. Given that the situation has rapidly evolved in Australia and New Zealand, we have decided to pos... -
ASCIA COVID-19 Update
16 March 2020: In response to the COVID-19 infectious respiratory disease outbreak caused by the most recently discovered coronavirus, ASCIA has developed a number of resources, including a new open access ASCIA webpage dedicated to COVID-19 information. The situation regard... -
ASCIA information about COVID-19
12 March 2020: ASCIA has developed the following resources in response to the COVID-19 infectious respiratory disease outbreak caused by the most recently discovered coronavirus, which are available open access on the ASCIA COVID-19 webpage https://www.allergy.org.au/members... -
Supply update - EpiPen® adrenaline (epinephrine) autoinjectors
9 March 2020: Mylan Australia has advised that despite there being sufficient supply of EpiPen®. unprecedented, disproportionate demand has meant that some pharmacies are experiencing supply delays and are seeing stock outages at some wholesalers, To ensure equitable distrib... -
Hymenoptera® venom product supply update
9th March 2020: There is currently limited stock of Hymenoptera® Honey Bee venom in Australia and New Zealand. This is due to critical manufacturing issues at Jubilant HollisterStier LLC, which negatively impacts their ability to ship venoms outside of the USA in the short t... -
Updated ASCIA OIT for food allergy information
4 March 2020: Oral immunotherapy (OIT) is a potential treatment for food allergy. It involves giving gradually increasing amounts of food allergen under medical supervision and continued daily consumption of the food allergen. If the goal of desensitisation is reached, there... -
Updated ASCIA HAE information
1 March 2020: ASCIA has updated its information on hereditary angioedema (HAE), to be consistent with international guidelines and include new treatments, and the following resources are now available on the ASCIA website www.allergy.org.au/hp/papers/hereditary-angioedema Up...
About ASCIA
ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases
Quick Links
About ASCIA
ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...
The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...
Disclaimer I Privacy
The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...
ASCIA respects your privacy. Read our privacy policy here...
Sponsors | Advertising
ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.
The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.
Accreditiation
This site complies with the HONcode standard for trustworthy health information: verify here.